These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27997699)

  • 41. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
    Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
    Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
    Le Gallo M; O'Hara AJ; Rudd ML; Urick ME; Hansen NF; O'Neil NJ; Price JC; Zhang S; England BM; Godwin AK; Sgroi DC; ; Hieter P; Mullikin JC; Merino MJ; Bell DW
    Nat Genet; 2012 Dec; 44(12):1310-5. PubMed ID: 23104009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
    Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
    Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An integrated molecular profile of endometrioid ovarian cancer.
    Pierson WE; Peters PN; Chang MT; Chen LM; Quigley DA; Ashworth A; Chapman JS
    Gynecol Oncol; 2020 Apr; 157(1):55-61. PubMed ID: 32139151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular pathology of endometrial carcinoma.
    Matias-Guiu X; Prat J
    Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
    Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
    Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
    Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
    Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
    J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
    Zhang X; Dong Y; Ti H; Zhao J; Wang Y; Li T; Zhang B
    Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
    Costigan DC; Dong F; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Endometrial carcinoma and precursor lesions].
    Djordjević B; Stanojević Z
    Srp Arh Celok Lek; 2007; 135(3-4):230-4. PubMed ID: 17642468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
    Stewart CJ; Amanuel B; Grieu F; Carrello A; Iacopetta B
    J Clin Pathol; 2010 Jul; 63(7):604-8. PubMed ID: 20591910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.